A5068686993- Vasculitis and related conditions
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Otitis Media and Relapsing Polychondritis
- Renal Diseases and Glomerulopathies
- Urticaria and Related Conditions
- Sarcoidosis and Beryllium Toxicity Research
- Systemic Lupus Erythematosus Research
- Heparin-Induced Thrombocytopenia and Thrombosis
- SARS-CoV-2 and COVID-19 Research
- Cell Adhesion Molecules Research
- Immunodeficiency and Autoimmune Disorders
- Eosinophilic Disorders and Syndromes
- Chronic Lymphocytic Leukemia Research
- Eosinophilic Esophagitis
- Platelet Disorders and Treatments
- COVID-19 Clinical Research Studies
- Gastroesophageal reflux and treatments
- Liver Diseases and Immunity
- Long-Term Effects of COVID-19
- Systemic Sclerosis and Related Diseases
- Monoclonal and Polyclonal Antibodies Research
- IgG4-Related and Inflammatory Diseases
- Autoimmune and Inflammatory Disorders
- Transplantation: Methods and Outcomes
- COVID-19 Impact on Reproduction
Cambridge University Hospitals NHS Foundation Trust
2015-2025
Addenbrooke's Hospital
2015-2025
University of Cambridge
2016-2025
University of Manchester
2025
Manchester Academic Health Science Centre
2025
University College London
2008-2022
Hammersmith Hospital
1998-2022
Imperial College London
2008-2022
University Hospitals of Leicester NHS Trust
2022
The Francis Crick Institute
2022
Cyclophosphamide induction regimens for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis are effective in 70 to 90% of patients, but they associated with high rates death and adverse events. Treatment rituximab has led remission 80 among patients refractory ANCA-associated may be safer than cyclophosphamide regimens.We compared as therapy vasculitis. We randomly assigned, a 3:1 ratio, 44 newly diagnosed renal involvement standard glucocorticoid regimen plus either at dose 375...
<h3>Abstract</h3> Mouse models are critical in pre-clinical studies of cancer therapy, allowing dissection mechanisms through chemical and genetic manipulations that not feasible the clinical setting. In tumour microenvironment (TME), novel highly multiplexed imaging methods can provide a rich source information. However, application such technologies mouse tissues is still its infancy. Here we present workflow for studying TME using mass cytometry with panel 27 antibodies on frozen tissues....
Abstract Objective Current treatments for systemic lupus erythematosus (SLE) and vasculitis contribute to mortality incapacity are only partially effective; thus, newer therapies clearly needed. Depletion of B cells has led disease control in patients with autoimmune disorders. We sought assess the long‐term efficacy safety a cell–depleting therapy SLE vasculitis. Methods In prospective study median followup 24 months, 11 active or refractory antineutrophil cytoplasmic antibody–associated...
Abstract Objective B cell depletion with rituximab has allowed remissions in relapsing or refractory antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis small studies. The aim of this study was to determine the efficacy and safety for ANCA‐associated a larger multicenter cohort. This permitted comparison dosing regimens, value continuing immunosuppression, investigation ANCA levels as re‐treatment biomarkers. Methods Retrospective, standardized data collection from 65 sequential...
Rituximab is effective induction therapy in refractory or relapsing antineutrophil cytoplasmic antibody-associated vasculitis (AAV). However, further relapse common, and maintenance strategies are required. The aim of this study was to reduce rates using a fixed-interval rituximab re-treatment protocol.Retrospective, standardized collection data from sequential patients receiving for AAV at single center studied. Group A (n = 28) received (4 infusions 375 mg/m(2) 2 1 gm) the time subsequent...
Objectives The RITUXVAS trial reported similar remission induction rates and safety between rituximab cyclophosphamide based regimens for antineutrophil cytoplasm antibody (ANCA)-associated vasculitis at 12 months; however, immunosuppression maintenance requirements longer-term outcomes after in ANCA-associated renal are unknown. Methods Forty-four patients with newly diagnosed involvement were randomised, 3:1, to glucocorticoids plus either (375 mg/m 2 /week×4) two intravenous pulses (n=33,...
Cyclophosphamide induction regimens are effective for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), but associated with infections, malignancies and infertility. Mycophenolate mofetil (MMF) has shown high remission rates in small studies of AAV.We conducted a randomised controlled trial to investigate whether MMF was non-inferior cyclophosphamide AAV. 140 newly diagnosed patients were randomly assigned or pulsed cyclophosphamide. All received the same oral...
Evaluation of rituximab and glucocorticoids as therapy to induce remission after relapse in ANCA-associated vasculitis (AAV) a prospective observational cohort patients enrolled into the induction phase RITAZAREM trial.
Objective Following induction of remission with rituximab in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) relapse rates are high, especially patients history relapse. Relapses associated increased exposure to immunosuppressive medications, the accrual damage and morbidity mortality. The RITAZAREM trial compared efficacy repeat-dose daily oral azathioprine for prevention relapsing AAV whom was reinduced rituximab. Methods an international randomised controlled, open-label,...
Rituximab is a B cell depleting anti-CD20 monoclonal antibody. CD20 not expressed on mature plasma cells and accordingly rituximab does have immediate effects immunoglobulin levels. However, after some patients develop hypogammaglobulinaemia.We performed single centre retrospective review of 177 with multisystem autoimmune disease receiving between 2002 2010. The incidence, severity complications hypogammaglobulinaemia were investigated.Median dose was 6 g (1-20.2) total follow-up 8012...
ANCA-associated vasculitis (AAV) is characterized by a chronic relapsing course. Rituximab (RTX) an effective maintenance treatment; however, the long-term outcomes after its discontinuation are unclear. The aim of this study was to explore AAV patients treated with repeat-dose RTX therapy.AAV receiving treatment protocol consisting induction and phase were included. For initial remission induction, dosed at 1 g every 2 weeks or 375 mg/m(2) weekly for 4 consecutive 6 months 24 months. At...
Objective We aimed to assess risk factors for the development of severe infection in patients with antineutrophil cytoplasm antibody-associated vasculitis (AAV) receiving rituximab. Methods 192 AAV were identified. Univariate and multivariate analyses performed identify following Severe infections classified as grade ≥3 proposed by Common Terminology Criteria Adverse Events V.4.0. Results 95 recorded 49 (25.52%) patients, corresponding an event rate 26.06 per 100 person-years. The...
Histopathological features in renal biopsies of patients with antineutrophil cytoplasmic antibody-associated vasculitis have predictive value for outcome who receive standard treatment cyclophosphamide and corticosteroids; however, whether the same holds true rituximab-treated is unknown. We describe associations between histopathology outcomes among treated a rituximab-based regimen Randomized Trial Rituximab versus Cyclophosphamide ANCA-Associated Vasculitis trial. Two pathologists,...
<h3>Background</h3> The long-term prognosis of Henoch-Schönlein Purpura (HSP) is predominantly determined by the extent renal involvement. There no consensus as to whether treatment with prednisolone at presentation can prevent or ameliorate progression nephropathy in HSP. <h3>Methods</h3> Children under 18 years age new-onset HSP were randomly assigned receive placebo for 14 days. primary outcomes (a) presence proteinuria 12 months (defined urine protein : creatinine ratio (UP UC) >20...
Objective. To describe pulmonary involvement at time of diagnosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV), as defined by computed tomography (CT). Methods. Patients with thoracic CT performed on or after the onset AAV (n = 140; 75 women; granulomatosis polyangiitis, n 79; microscopic polyangiitis MPA, 61) followed a tertiary referral center clinic were studied. Radiological patterns evaluated from studies using predefined protocol, and compared to...
Eosinophilic granulomatosis with polyangiitis (EGPA) is a subset of antineutrophil cytoplasmic antibodies (ANCA) associated vasculitis distinct pathophysiological mechanisms, clinical features and treatment responses. Rituximab licensed therapy for microscopic but there limited experience rituximab in EGPA.EGPA patients from tertiary centre who received mostly refractory EGPA or whom cyclophosphamide was contra indicated were studied. A standardised dataset collected at time initial every 3...
Pulmonary haemorrhage with hypoxia caused by anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) has a high early mortality. Avacopan, an oral C5a receptor antagonist, is approved treatment for AAV, but patients pulmonary requiring invasive ventilation support were excluded from the Avacopan Treatment of ANCA-Associated Vasculitis (ADVOCATE) Trial.
Objectives: This study aimed to evaluate the response of refractory Wegener’s granulomatosis affecting ear, nose and throat granulomatous eye disease B‐cell depletion with rituximab. Design: A retrospective case note review. Setting: Tertiary Centre. Participants: All patients who received rituximab for head neck were included. Main outcome measures: Demographic follow‐up data at five time points recorded. Response was measured using change in Birmingham Vasculitis Activity Score...
Background. Systemic lupus erythematosus is a relapsing autoimmune disease. Conventional therapy increases the risk of infection and malignancies; furthermore, minority patients suffer from refractory B-cell depletion with chimeric +AFw-anti-CD20 monoclonal antibody, rituximab, an alternative for systemic erythematosus. We sought to assess long-term efficacy safety rituximab in this patient subgroup.